Amgen announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed Tezspire (tezepelumab-ekko) demonstrated reductions in the annualized asthma… read more.
A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human… read more.
A new study, led by researchers from the University of California, Irvine, identifies a reason for why older adults are significantly more susceptible to infectious diseases than younger… read more.
A small preliminary study from Northwestern Medicine has shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19. The… read more.
NICE (UK)-Palforzia from Aimmune/Nestle is recommended, within its marketing authorisation, as an option for treating peanut allergy in children aged 4 to 17. It can be continued in… read more.
Not too long ago the idea of taking, for instance a skin cell and transforming it into a muscle cell was unthinkable. About 10 years ago, however, revolutionary… read more.
The FDA approved the only biologic for severe asthma without any phenotype or biomarker limitations, manufacturers AstraZeneca and Amgen announced. The first-in-class biologic tezepelumab-ekko (Tezspire) is indicated as an… read more.
The biologic drug dupilumab lowers the rate of severe asthma attacks and improves lung function and asthma control for children ages 6 to 11, researchers reported on December 9, 2021 in… read more.
A pharmacogenomic testing service involves more than simply reporting that a patient has a genetic variant that affects the way they respond to a drug. In a session… read more.
Asthma afflicts more than 300 million people worldwide. The most severe manifestation, known as non-Th2, or non-atopic childhood asthma, represents the majority of the cases, greater than 85%,… read more.
Takeda Pharmaceutical announced results from two final analyses from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), which evaluated the long-term safety (primary endpoint)… read more.
Scientists isolated a molecule, extracted from the leaves of the European chestnut tree, with the power to neutralize dangerous, drug-resistant staph bacteria. Frontiers in Pharmacology published the finding, led by… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
